Biogen - Latest Emails, Sales & DealsNew Form 8-K for Biogen Inc.January 15, 2025 - 1 day agoFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s DiseaseJanuary 14, 2025 - 2 days agoBiogen Appoints Adam Feire as Head of Business Development and External InnovationJanuary 9, 2025 - 7 days agoNew Form 3 for Biogen Inc.January 8, 2025 - 8 days agoNew Form 4 for Biogen Inc.December 9, 2024 - 1 month agoNew Form 4 for Biogen Inc.December 9, 2024 - 1 month agoNew Form 144 for Biogen Inc.December 9, 2024 - 1 month agoBiogen Appoints Tim Power as Head of Investor RelationsDecember 9, 2024 - 1 month agoSamsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™December 6, 2024 - 1 month ago“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in MexicoDecember 5, 2024 - 1 month ago“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South KoreaNovember 28, 2024 - 1 month agoDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityNovember 19, 2024 - 1 month agoEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s DiseaseNovember 14, 2024 - 2 months agoNew Form SC 13G/A for Biogen Inc.November 13, 2024 - 2 months agoNew Form SC 13G/A for Biogen Inc.November 8, 2024 - 2 months agoNew Form SC 13G/A for Biogen Inc.November 8, 2024 - 2 months agoNew Form 4 for Biogen Inc.November 8, 2024 - 2 months agoNew Form 4 for Biogen Inc.November 5, 2024 - 2 months agoEisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track StatusNovember 1, 2024 - 2 months agoEisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceOctober 31, 2024 - 2 months agoNew Form 10-Q for Biogen Inc.October 31, 2024 - 2 months agoNew Form 8-K for Biogen Inc.October 31, 2024 - 2 months agoNew Form 8-K for Biogen Inc.October 30, 2024 - 2 months agoBiogen Reports Third Quarter 2024 ResultsOctober 30, 2024 - 2 months agoBiogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesOctober 30, 2024 - 2 months agoBiogen Appoints Daniel Quirk, MD, as Chief Medical OfficerOctober 29, 2024 - 2 months agoMichael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025October 28, 2024 - 2 months agoBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024October 27, 2024 - 2 months agoBiogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceOctober 24, 2024 - 2 months agoBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024October 22, 2024 - 2 months agoUpdate on Regulatory Review of Lecanemab for Early Alzheimer's Disease in AustraliaOctober 17, 2024 - 3 months agoNew Form SC 13G for Biogen Inc.October 17, 2024 - 3 months agoBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsOctober 9, 2024 - 3 months agoNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMAOctober 8, 2024 - 3 months agoNew Form 3 for Biogen Inc.October 7, 2024 - 3 months agoBiogen to Report Third Quarter 2024 Financial Results October 30, 2024October 2, 2024 - 3 months agoUCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024September 24, 2024 - 3 months agoSamsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™September 22, 2024 - 3 months agoNew Form 8-K for Biogen Inc.September 12, 2024 - 4 months agoBiogen Board Appoints Two New Independent DirectorsSeptember 12, 2024 - 4 months agoBiogen to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 5, 2024 - 4 months agoNew Form 4 for Biogen Inc.September 5, 2024 - 4 months agoBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMASeptember 4, 2024 - 4 months agoNew Form 144 for Biogen Inc.September 3, 2024 - 4 months agoLeqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great BritainAugust 22, 2024 - 4 months agoNew Form SC 13G/A for Biogen Inc.August 17, 2024 - 5 months agoNew Form 8-K for Biogen Inc.August 15, 2024 - 5 months ago“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab EmiratesAugust 14, 2024 - 5 months agoNew Form SC 13G/A for Biogen Inc.August 7, 2024 - 5 months agoNew Form 10-Q for Biogen Inc.August 1, 2024 - 5 months agoNew Form 8-K for Biogen Inc.August 1, 2024 - 5 months agoBiogen Reports Second Quarter 2024 ResultsAugust 1, 2024 - 5 months agoNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024July 31, 2024 - 5 months agoBiogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s DiseaseJuly 30, 2024 - 5 months agoUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European UnionJuly 26, 2024 - 5 months agoSage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential TremorJuly 24, 2024 - 5 months ago“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in IsraelJuly 11, 2024 - 6 months ago“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong KongJuly 11, 2024 - 6 months agoBiogen Completes Acquisition of Human Immunology BiosciencesJuly 2, 2024 - 6 months ago“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in ChinaJune 28, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 4 for Biogen Inc.June 25, 2024 - 6 months agoNew Form 8-K for Biogen Inc.June 25, 2024 - 6 months agoBiogen to Report Second Quarter 2024 Financial Results August 1, 2024June 24, 2024 - 6 months agoTOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European UnionJune 24, 2024 - 6 months agoNew Form S-8 for Biogen Inc.June 20, 2024 - 6 months agoBiogen Announces Webcast of Annual Meeting of StockholdersJune 10, 2024 - 7 months agoFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s DiseaseJune 9, 2024 - 7 months agoBiogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air TravelJune 3, 2024 - 7 months agoBiogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALSMay 30, 2024 - 7 months agoBiogen to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 30, 2024 - 7 months ago“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South KoreaMay 26, 2024 - 7 months ago“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South KoreaMay 26, 2024 - 7 months agoBiogen to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 - 7 months agoBiogen to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 - 7 months agoBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology BiosciencesMay 22, 2024 - 7 months agoBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 16, 2024 - 8 months agoStatement: Biogen Shares Update on Angelman Syndrome ProgramMay 16, 2024 - 8 months agoEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track StatusMay 14, 2024 - 8 months agoNew Form 4 for Biogen Inc.May 4, 2024 - 8 months agoBiogen Reports Progress on Corporate Responsibility PrioritiesMay 3, 2024 - 8 months agoNew Form ARS for Biogen Inc.April 26, 2024 - 8 months agoNew Form DEF 14A for Biogen Inc.April 26, 2024 - 8 months agoNew Form DEFA14A for Biogen Inc.April 26, 2024 - 8 months ago123LatestFind More Emails, Deals & Sales From These StoresLost Golf BallsMPRParker's British InstitutionPehr Maverick & Co.Fireball WhiskyRugabubMantra LabsSTAAHBarker ShoesBaby BluesAspire DrinksAdept CosmeticsCharlie B CollectionBumble and bumble UKB.YELLOWTAILEpny GolfCandles DirectTwo JeysUniversity of Oregon